PITTSBURGH, Jan. 5, 2015 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced the U.S. launch of its Valsartan
Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is
the generic version of Novartis' Diovan® Tablets. Mylan
received final approval from the U.S. Food and Drug Administration
(FDA) for its Abbreviated New Drug Application (ANDA) for this
product, which is indicated for the treatment of hypertension, to
lower blood pressure.(1)
Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320
mg, had U.S. sales of approximately $2
billion for the 12 months ending September 30, 2014, according to IMS Health.
Currently, Mylan has 284 ANDAs pending FDA approval representing
$109.2 billion in annual brand sales,
according to IMS Health. Forty-four of these pending ANDAs are
potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12
months ending June 30, 2014,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 25,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at
mylan.com.
(1) Valsartan Tablets can cause injury and death to the
developing fetus and therefore should be discontinued if pregnancy
occurs. It should also not be administered in people who are
allergic to any component of the product or co-administered with
aliskiren in patients with diabetes. Signs and symptoms of
hypotension should be monitored as well as renal function and
potassium levels.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-diovan-tablets-300015701.html
SOURCE Mylan Inc.